Vitrolife AB (publ)

OM:VITR Stock Report

Market Cap: SEK 13.0b

Vitrolife Valuation

Is VITR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of VITR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: VITR (SEK96.2) is trading below our estimate of future cash flow value (SEK171.77)

Significantly Below Future Cash Flow Value: VITR is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VITR?

Key metric: As VITR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VITR. This is calculated by dividing VITR's market cap by their current revenue.
What is VITR's PS Ratio?
PS Ratio3.8x
SalesSEK 3.41b
Market CapSEK 12.99b

Price to Sales Ratio vs Peers

How does VITR's PS Ratio compare to its peers?

The above table shows the PS ratio for VITR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average15x
BIOG B BioGaia
8.1x10.81%SEK 12.6b
BONEX Bonesupport Holding
12.3x23.24%SEK 15.2b
HNSA Hansa Biopharma
17.2x35.37%SEK 3.2b
BIOA B BioArctic
22.3x28.74%SEK 25.0b
VITR Vitrolife
3.8x6.70%SEK 13.0b

Price-To-Sales vs Peers: VITR is good value based on its Price-To-Sales Ratio (3.8x) compared to the peer average (15x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does VITR's PS Ratio compare vs other companies in the SE Biotechs Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
CANTA Cantargia
1.7x-47.92%US$54.73m
SPRINT Sprint Bioscience
2.6x3.56%US$40.71m
XBRANE Xbrane Biopharma
2.9x34.32%US$22.25m
SUBGEN Subgen AI
0.3xn/aUS$8.39m
VITR 3.8xIndustry Avg. 11.1xNo. of Companies10PS01224364860+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VITR is good value based on its Price-To-Sales Ratio (3.8x) compared to the Swedish Biotechs industry average (11.1x).

Price to Sales Ratio vs Fair Ratio

What is VITR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VITR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.8x
Fair PS Ratio3.7x

Price-To-Sales vs Fair Ratio: VITR is expensive based on its Price-To-Sales Ratio (3.8x) compared to the estimated Fair Price-To-Sales Ratio (3.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VITR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 96.20
SEK 162.75
+69.18%
19.33%SEK 215.00SEK 131.00n/a4
Jun ’27SEK 98.25
SEK 162.75
+65.65%
19.33%SEK 215.00SEK 131.00n/a4
May ’27SEK 104.70
SEK 162.67
+55.36%
23.10%SEK 215.00SEK 115.00n/a6
Apr ’27SEK 96.20
SEK 163.40
+69.85%
25.75%SEK 215.00SEK 110.00n/a5
Mar ’27SEK 95.40
SEK 176.75
+85.27%
20.57%SEK 215.00SEK 132.00n/a4
Feb ’27SEK 116.20
SEK 187.00
+60.93%
17.56%SEK 225.00SEK 141.00n/a4
Jan ’27SEK 137.00
SEK 188.75
+37.77%
18.07%SEK 230.00SEK 141.00n/a4
Dec ’26SEK 146.00
SEK 193.50
+32.53%
14.40%SEK 230.00SEK 160.00n/a4
Nov ’26SEK 147.30
SEK 193.50
+31.36%
14.40%SEK 230.00SEK 160.00n/a4
Oct ’26SEK 134.90
SEK 199.25
+47.70%
18.07%SEK 240.00SEK 160.00n/a4
Sep ’26SEK 138.60
SEK 202.50
+46.10%
18.60%SEK 240.00SEK 160.00n/a4
Aug ’26SEK 141.10
SEK 202.50
+43.52%
18.60%SEK 240.00SEK 160.00n/a4
Jul ’26SEK 141.30
SEK 228.75
+61.89%
14.61%SEK 265.00SEK 175.00n/a4
Jun ’26SEK 155.20
SEK 242.40
+56.19%
6.82%SEK 265.00SEK 227.00SEK 98.255
May ’26SEK 157.60
SEK 243.40
+54.44%
7.26%SEK 265.00SEK 227.00SEK 104.705
Apr ’26SEK 165.70
SEK 256.60
+54.86%
5.46%SEK 268.00SEK 230.00SEK 96.205
Mar ’26SEK 197.00
SEK 269.20
+36.65%
2.43%SEK 278.00SEK 260.00SEK 95.405
Feb ’26SEK 223.40
SEK 270.20
+20.95%
2.83%SEK 280.00SEK 260.00SEK 116.205
Jan ’26SEK 215.00
SEK 273.33
+27.13%
3.45%SEK 280.00SEK 260.00SEK 137.003
Dec ’25SEK 224.80
SEK 273.33
+21.59%
3.45%SEK 280.00SEK 260.00SEK 146.003
Nov ’25SEK 231.40
SEK 271.67
+17.40%
3.13%SEK 280.00SEK 260.00SEK 147.303
Oct ’25SEK 251.20
SEK 271.67
+8.15%
3.13%SEK 280.00SEK 260.00SEK 134.903
Sep ’25SEK 247.00
SEK 261.67
+5.94%
3.93%SEK 275.00SEK 250.00SEK 138.603
Aug ’25SEK 231.20
SEK 261.67
+13.18%
3.93%SEK 275.00SEK 250.00SEK 141.103
Jul ’25SEK 172.90
SEK 231.67
+33.99%
10.33%SEK 265.00SEK 210.00SEK 141.303
Jun ’25SEK 184.70
SEK 231.67
+25.43%
10.33%SEK 265.00SEK 210.00SEK 155.203
SEK 162.75
Fair Value
40.9% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 17:33
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vitrolife AB (publ) is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kallum TitchmarshBofA Global Research
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB